DGX
Quest Diagnostics Incorporated
Set alert
- YTD
- +45.12%
- 1 year
- +43.28%
- Open
- 255.14
- Prev close
- 252.92
- Mkt cap
- 27.79B
- Vol
- 919.59K
- Avg vol
- 991.96K
- EPS
- 10.04
- P/E
- 25.08
- Div yield
- 1.36%
More statistics
- Low
- 250.95
- High
- 256.99
- Forward P/E
- 21.02
- Beta
- 0.54
- Short ratio
- 3.05
- Inst. own
- 98.88%
- Dividend
- 3.44
- Ex-div date
- Oct 5, 2026
- Earnings
- Feb 9, 2027
- 50-d avg
- 238.33
- 200-d avg
- 211.82
- 1y target
- 257.27
Key statistics
- Market cap
- 27.79B
- Enterprise value
- 33.83B
- Trailing P/E
- 25.07
- Forward P/E
- 21.02
- PEG ratio
- 1.65
- Price / sales
- 2.35
- Price / book
- 3.63
- EPS (TTM)
- 10.04
- Beta
- 0.54
- Dividend yield
- 1.36%
- Payout ratio
- 25.10%
- Profit margin
- 9.54%
- Revenue (TTM)
- 11.84B
- Revenue growth
- 10.00%
- Free cash flow
- 872.50M
- Total cash
- 797.00M
- Total debt
- 6.40B
- Return on equity
- 15.32%
- Shares outstanding
- 110.37M
- Short % of float
- 3.25%
- 50-day average
- 238.33
- 200-day average
- 211.82
Analyst view
Consensus: buy
- Target (low)
- 235.00
- Target (mean)
- 257.27
- Target (high)
- 279.00
- Strong buy2
- Buy7
- Hold8
- Sell0
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 2.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 2.68 | — | — | — |
| Oct 22, 2026 | Sep 30, 2026 | 2.87 | 3.00 | +0.13 | +4.53% |
| Jul 23, 2026 | Jun 30, 2026 | 2.82 | 3.12 | +0.30 | +10.64% |
| Apr 21, 2026 | Mar 31, 2026 | 2.37 | 2.50 | +0.13 | +5.49% |
| Feb 10, 2026 | Dec 31, 2025 | 2.36 | 2.42 | +0.06 | +2.54% |
| Oct 21, 2025 | Sep 30, 2025 | 2.50 | 2.60 | +0.10 | +4.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Sep 21, 2026 | Truist Securities | main | Hold | Hold |
| Sep 8, 2026 | UBS | main | Neutral | Neutral |
| Jul 28, 2026 | JP Morgan | main | Neutral | Neutral |
| Jul 24, 2026 | UBS | main | Neutral | Neutral |
| Jul 24, 2026 | Mizuho | main | Outperform | Outperform |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- questdiagnostics.com
News
- Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
- Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
- Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's
- Quest Diagnostics Incorporated $DGX Stock: Yousif Capital Management LLC Raises Holdings
- Quest Diagnostics Bumps Guidance While Managing Quanum System Breach
- Quest Diagnostics Q3 2026 Earnings Call Transcript
- Quest Diagnostics Discloses Unauthorized Access To Its Testing Management Platform Quanum LSM System; Company Promptly Initiated Its Cybersecurity Incident Response Procedures To Contain The Activity; Sees No Material Disruption
- Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 Est
- Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est
- Quest Diagnostics Q3 Adj. EPS $3.00 Beats $2.86 Estimate, Sales $3.097B Beat $3.046B Estimate
Your note
Sign in to keep a note on DGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIS J E CAUSEY | Chief Executive Officer | Stock Award(Grant) | Mar 3, 2026 | 142,423 |
| DAVIS JAMES E | Chief Executive Officer | Sale | Aug 31, 2026 | 122,423 |
| DEPPE MICHAEL J | Officer | Stock Award(Grant) | Mar 3, 2026 | 35,196 |
| DOHERTY CATHERINE T | Officer | Sale | Mar 4, 2026 | 71,624 |
| GREGG VICKY B | Director | Stock Award(Grant) | Jul 21, 2026 | 18,386 |
| MAIN TIMOTHY L | Director | Purchase | Jul 21, 2026 | 27,460 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.43% | 9,275,411 | 2.34B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.57% | 7,233,394 | 1.82B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.57% | 6,131,045 | 1.54B | Jun 29, 2026 |
| State Street Corporation | 5.01% | 5,516,643 | 1.39B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.95% | 5,444,986 | 1.37B | Jun 29, 2026 |
| Boston Partners | 4.31% | 4,744,473 | 1.19B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 3,514,526 | 884.78M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 2,868,317 | 722.10M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.18% | 2,398,588 | 603.84M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.34% | 1,470,712 | 370.25M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.31% | 1,436,934 | 361.75M | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.25% | 1,373,267 | 345.72M | Sep 29, 2026 |